Gilead and Kite’s ASH 2026 update is the focus of this story, but the supplied headline doesn’t name the studies or explain what they found.
Gilead Sciences and Kite announced new data across their pipeline and portfolio at the 2026 American Society of Hematology meeting, according to the November 4 headline. The available information doesn’t identify the treatments or studies, describe the results, or say whether the findings changed development plans. Gilead shares closed at US$176.02, up 4.19% for the day.
Investor takeaway: The headline points to new Gilead and Kite data, but there isn’t enough detail to judge the findings or their potential business impact.
Gilead Sciences Inc
GILD.US
GILD.US
Gilead Sciences Inc
WealthAwesomeMarket cap
$207.72B
Div. yield
1.91%
Div. / share
$3.25
52W high
$175.65
52W low
$114.31
1W change
+9.60%
Beta
0.37
Analyst Price Targets
Based on 28 analysts covering GILD · as of Nov 4, 2026
Wall Street analysts forecast GILD stock price to fall 1.1% over the next 12 months.
Consensus
Buy4.32 / 5.00
Avg. Target
C$172.50
-1.1% Upside
Previously C$170.88 on Nov 2, 2026
Current Price
C$174.48
Last close
Analyst Breakdown (28 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GILD's historical volatility
30-Day Vol
30.0%
Annualized
90-Day Vol
28.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$208.59
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$185.18 | C$166.98 – C$205.36 |
| 60 trading days | C$196.54 | C$169.79 – C$227.50 |
| 90 trading days | C$208.59 | C$174.38 – C$249.52 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Gilead closed at US$176.02
Shares finished 4.19% above the previous close. Reported volume was 876,274 shares, below the 20-day average of 6,550,424.
Bull case
The announcement points to new data across Gilead and Kite’s pipeline and portfolio at a major hematology meeting. Investors can look for more detail on the programs involved.
Bear case
The headline doesn’t name the studies, report results, or identify development milestones. On its own, it doesn’t show the update’s clinical significance or commercial implications.
What happened: Gilead and Kite shared new ASH data
The November 4 headline says Gilead and Kite presented new data across their pipeline and portfolio at ASH 2026. It doesn’t name the therapies, studies, or patient groups, or summarize the results. Based on the available information, it’s not possible to tell whether the update covers early research, later-stage trials, or existing products. Investors can find company information on Gilead Sciences’ stock page, but the headline provides few details about the event.
What the numbers show: shares rose, volume was below average
Gilead closed at US$176.02, up 4.19% for the day. Reported volume was 876,274 shares, compared with a 20-day average of 6,550,424; the supplied volume comparison is 1.47x. The stock was up 9.60% over one week, 20.64% over one month, and 46.07% year to date. These figures show how the shares performed, but the available information doesn’t establish that the ASH announcement caused the move. See Gilead’s stock page for its quote and company information.
What to watch next: the studies and results behind the headline
The key details to look for are which Gilead or Kite programs were presented at ASH and what the data showed. The headline refers to the pipeline and portfolio, but the available information includes no efficacy or safety results, trial stages, regulatory updates, or company guidance. Without those details, investors can’t assess the update’s implications for development plans or the business. The information provided identifies a data announcement, but no further milestone or follow-up.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
